首页> 外文期刊>Therapeutic Drug Monitoring >Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges.
【24h】

Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges.

机译:免疫抑制剂的毒物动力学治疗药物监测:希望,现实和挑战。

获取原文
获取原文并翻译 | 示例
       

摘要

Although current immunosuppressive protocols have dramatically decreased acute rejection episodes, there has been less progress in terms of long-term graft survival after kidney transplantation over the last 2 decades. The key to reducing the damage to a transplanted organ as caused by chronic processes is early detection. Modern screening technologies in the fields of genetics, genomics, protein profiling (proteomics), and biochemical profiling (metabolomics) have opened new opportunities for the development of sensitive and specific diagnostic tools. Metabolic profiling appears to be a promising strategy because changes in the cell biochemistry are ultimately responsible for the histologic and pathophysiologic changes of the transplanted kidney and are most likely already detectable before histologic and pathophysiologic changes occur. Using truly no-targeted screening technologies as clinical diagnostic tools is not yet feasible, mostly because of the complexity of the data generated and the lack ofalgorithms to convert this information into clinically applicable information. A realistic and powerful targeted approach is the development of combinatorial biomarkers. These are biomarker patterns that typically consist of five or more individual parameters. Combined biomarker patterns confer significantly more information than a single measurement and, thus, can be expected to have better specificity and sensitivity. A series of studies in rats and healthy individuals evaluating the effects of immunosuppressants on urine metabolite patterns showed that immunosuppressant-induced changes of metabolite patterns in urine were associated with a combination of changes in glomerular filtration, changes in secretion/absorption by tubulus cells, and changes in kidney cell metabolism. These studies suggested that a combination of biomarkers that can be used for toxicodynamic therapeutic drug monitoring of immunosuppressants should include urine metabolites that constitute valid surrogate markers of these kidney functions.
机译:尽管目前的免疫抑制方案已大大减少了急性排斥反应发作,但在过去的20年中,肾脏移植后长期移植物存活方面的进展较少。减少慢性过程对移植器官造成损害的关键是及早发现。遗传学,基因组学,蛋白质谱(蛋白质组学)和生化谱(代谢组学)领域中的现代筛选技术为开发灵敏和特定的诊断工具开辟了新机会。代谢谱分析似乎是一种有前途的策略,因为细胞生物化学的变化最终导致了移植肾脏的组织学和病理生理学改变,并且很可能在组织学和病理生理学改变发生之前就已经可以检测到。使用真正的无目标筛查技术作为临床诊断工具尚不可行,这主要是因为所生成数据的复杂性以及缺乏将该信息转换为临床适用信息的算法。现实而强大的针对性方法是开发组合生物标记。这些是生物标记模式,通常由五个或更多单独参数组成。组合的生物标志物模式可提供比单次测量更多的信息,因此可以预期具有更好的特异性和敏感性。在大鼠和健康个体中进行的一系列评估免疫抑制剂对尿液代谢产物模式影响的研究表明,免疫抑制剂诱导的尿液中代谢产物模式变化与肾小球滤过变化,肾小管细胞分泌/吸收变化以及肾脏细胞代谢的变化。这些研究表明,可用于免疫抑制剂毒物动力学治疗药物监测的生物标志物组合应包括构成这些肾功能的有效替代标志物的尿液代谢物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号